Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year....
Acrivon Therapeutics, Inc. is an oncology-focused biotech using a multi-targeted panel to identify patients for clinical trials. Acrivon Therapeutics is focused on ACR-368, a CHK1/2 inhibitor, with pr...
Here is how Acrivon Therapeutics, Inc. (ACRV) and Hims & Hers Health, Inc. (HIMS) have performed compared to their sector so far this year....
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing prec...
Here, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move....
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio....
WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precis...
Acrivon Therapeutics (ACRV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season....
Shares of Acrivon Therapeutics ACRV, -3.26% advanced in post-market trading after the biopharmaceutical company said it would present clinical trial data in connection with a biomarker test for ovaria...
• Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented• A 50% confirmed o...
At the end of the previous week, the Oracle of Omaha yet again boosted his stake in a media giant's tracking stocks, even with shares still in retreat....